154 related articles for article (PubMed ID: 23229801)
1. Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.
Conley AP; Guérin A; Sasane M; Gauthier G; Schwiep F; Keir CH; Wu EQ
J Gastrointest Cancer; 2013 Jun; 44(2):190-8. PubMed ID: 23229801
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach.
Conley AP; Guerin A; Sasane M; Gauthier G; Schwiep F; Keir CH; Wu EQ
J Gastrointest Cancer; 2014 Dec; 45(4):431-40. PubMed ID: 24847952
[TBL] [Abstract][Full Text] [Related]
4. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
5. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Corless CL; Ballman KV; Antonescu CR; Kolesnikova V; Maki RG; Pisters PW; Blackstein ME; Blanke CD; Demetri GD; Heinrich MC; von Mehren M; Patel S; McCarter MD; Owzar K; DeMatteo RP
J Clin Oncol; 2014 May; 32(15):1563-70. PubMed ID: 24638003
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
[TBL] [Abstract][Full Text] [Related]
10. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.
Li J; Gong JF; Wu AW; Shen L
Eur J Surg Oncol; 2011 Apr; 37(4):319-24. PubMed ID: 21277730
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
Kanda T; Nishida T; Wada N; Kobayashi O; Yamamoto M; Sawaki A; Boku N; Koseki M; Doi T; Toh Y; Kakeji Y; Sugiyama T; Komatsu Y; Kikuchi S; Ogoshi K; Katai H; Miyachi K; Hirota S; Ohtsu A
Int J Clin Oncol; 2013 Feb; 18(1):38-45. PubMed ID: 22105894
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
Joensuu H
Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
[TBL] [Abstract][Full Text] [Related]
13. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
14. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Blanke CD; Demetri GD; von Mehren M; Heinrich MC; Eisenberg B; Fletcher JA; Corless CL; Fletcher CD; Roberts PJ; Heinz D; Wehre E; Nikolova Z; Joensuu H
J Clin Oncol; 2008 Feb; 26(4):620-5. PubMed ID: 18235121
[TBL] [Abstract][Full Text] [Related]
15. [Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].
Heger U; Weitz J; Lordick F
Chirurg; 2008 Jul; 79(7):630-7. PubMed ID: 18548219
[TBL] [Abstract][Full Text] [Related]
16. Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy.
Kanda T; Ishikawa T; Hirota S; Yajima K; Kosugi S; Ohashi M; Suzuki S; Mashima Y; Ajioka Y; Hatakeyama K
Jpn J Clin Oncol; 2012 Jul; 42(7):578-85. PubMed ID: 22523393
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Dematteo RP; Ballman KV; Antonescu CR; Maki RG; Pisters PW; Demetri GD; Blackstein ME; Blanke CD; von Mehren M; Brennan MF; Patel S; McCarter MD; Polikoff JA; Tan BR; Owzar K;
Lancet; 2009 Mar; 373(9669):1097-104. PubMed ID: 19303137
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors.
Rutkowski P; Gronchi A
Oncologist; 2013 Jun; 18(6):689-96. PubMed ID: 23709752
[TBL] [Abstract][Full Text] [Related]
19. Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy.
Nikfarjam M; Kimchi E; Shereef S; Gusani NJ; Jiang Y; Liang J; Sehmbey M; Staveley-O'Carroll KF
J Gastrointest Surg; 2008 Nov; 12(11):2023-31. PubMed ID: 18546049
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]